Original from: Burning Rock 

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic products in China, jointly developing NGS-based CDx for Bayer's growing portfolio of precision cancer therapies.

"We are delighted to have established a companion diagnostics collaboration with Bayer, a global leader in the biopharmaceutical industry. Burning Rock is committed to the comprehensive development of companion diagnostics on a global scale, and we believe that through the integration of our resources and expertise in the field of cancer diagnosis and treatment, this collaboration will set a standard and high-quality model for the joint development of precision diagnostics. We aim to make a greater contribution to the advancement of precision oncology, providing more effective treatment options for patients and setting new benchmarks in the medical field," said Mr. Han, Founder and CEO of Burning Rock.

Source: Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines